Weight-loss jab ‘cuts heart disease deaths by 20%’
Semaglutide, also known as Ozempic or Wegovy, is set to transform treatments for cardiovascular disease, but a change in guidelines is needed to allow routine prescriptions
有史以来最大规模的索马鲁肽(也称为 Ozempic 或 Wegovy)研究发现,即使人们不减肥,这种药物也能将心脏病死亡率降低约 20%。
在威尼斯举行的欧洲肥胖大会上公布的研究结果被誉为自 20 世纪 90 年代引入他汀类药物以来最大的医学突破。